Revolutionizing Chronic Heart Failure Therapy
For millions of patients suffering from Heart Failure with Reduced Ejection Fraction (HFrEF), the primary struggle is an overworked heart and a nervous system stuck in a permanent state of "fight or flight." This autonomic imbalance—characterized by sympathetic overactivity and parasympathetic withdrawal—accelerates the progression of the disease, leading to frequent hospitalizations and a diminished quality of life.
The Harmony™ System was engineered to address this imbalance at its source. Unlike traditional cardiac devices that focus on rhythm management or mechanical pumping, Harmony™ uses high-precision radio-frequency (RF) powered neurostimulation to modulate the neural signals that regulate cardiac workload.
Core Technology and Mechanism of Action
The Harmony™ System consists of a miniaturized, lead-based neurostimulator that is implanted within the vascular system. Its function is based on three technological breakthroughs:
- Endovascular Neural Interface: The system interfaces with the autonomic nervous system via the internal jugular or femoral vein. This location allows for direct modulation of the neural pathways that control heart rate and ventricular wall stress without the need for invasive chest surgery.
- RF-Powered Architecture: The device is powered by an external radio-frequency transmitter. This design choice eliminates the need for large, internal batteries, allowing the implanted components to remain low-profile and reducing the long-term risks associated with battery depletion and replacement surgeries.
- Physiological Titration: The system provides titratable therapy, meaning clinicians can adjust the stimulation parameters based on the patient’s specific hemodynamic response. This ensures that the therapy remains optimized as the patient’s condition evolves over time.
The Implantation Procedure: Minimizing Risk, Maximizing Access
One of the most significant advantages of the Harmony™ System is its delivery method. The system is implanted during a standard, minimally invasive transcatheter procedure in a cardiac catheterization lab.
- Percutaneous Access: Using standard interventional techniques, the clinician gains access to the venous system.
- Guided Positioning: Under fluoroscopic guidance, the lead is navigated to the optimal neural stimulation site.
- Secure Fixation: A proprietary anchoring mechanism secures the lead against the vessel wall, ensuring long-term stability and consistent electrical contact.
This approach significantly reduces procedural trauma, risk of infection, and hospital recovery time, making it a viable option for high-risk patients who cannot tolerate traditional surgery.
Clinical Impact: Restoring Quality of Life
Clinical data from our ongoing research indicates that the Harmony™ System provides sustained benefits across multiple clinical markers. By reducing the sympathetic "noise" that drains the heart’s energy, the system facilitates a state of "cardiac rest," which leads to:
- Improved Ejection Fraction: Helping the heart pump more effectively over time.
- Reduced Hospital Readmissions: Breaking the cycle of acute heart failure episodes.
- Increased Functional Capacity: Allowing patients to return to daily activities, such as walking and climbing stairs, without debilitating fatigue.
Conclusion: The Future of Neuro-Cardiology
The Harmony™ System represents more than just a new device; it represents a new discipline in medicine. By combining the precision of interventional cardiology with the transformative power of neuromodulation, EnoPace Biomedical is providing a scalable, evidence-based solution to one of the most pressing challenges in modern healthcare.
